Tourbillon Capital Partners’s Krystal Biotech KRYS Stock Holding History

Tourbillon Capital Partners’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-141,198	Closed	-$2.48M	–	14
2018 Q3	$2.48M	Sell	141,198 -64,038	-31%	-$1.07M	0.27%	34
2018 Q2	$3.05M	Sell	205,236 -47,112	-19%	-$530K	0.12%	70
2018 Q1	$2.55M	Hold	252,348	–	–	0.1%	54
2017 Q4	$2.65M	Buy	252,348 +2,348	+0.9%	+$23.5K	0.1%	45
2017 Q3	$2.49M	Buy	+250,000	New	+$2.52M	0.06%	53

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Tourbillon Capital Partners's KRYS Position: Q4 2018 in Review

Tourbillon Capital Partners sold out of Krystal Biotech (KRYS) in Q4 2018, closing a stake of 141,198 shares — an estimated $2.48M sold.

Tourbillon Capital Partners first reported a position in KRYS in Q3 2017 and held it in 5 quarters. The position peaked at $3.05M in Q2 2018. 45 funds tracked by Wall St. Rank hold KRYS as of Q4 2018.

Tourbillon Capital Partners reported no remaining Krystal Biotech position as of Q4 2018 after selling out during the quarter.
Tourbillon Capital Partners sold 141,198 Krystal Biotech shares in Q4 2018, an estimated $2.48M.
Tourbillon Capital Partners first reported a position in Krystal Biotech in Q3 2017 and held it in 5 quarters.
Tourbillon Capital Partners's Krystal Biotech position peaked at $3.05M in Q2 2018.
45 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2018.

Based on Tourbillon Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.